About Pregmune

Science and Compassion,
in Service of Families

We're a team of physicians, clinicians, researchers, data scientists, and technology experts dedicated to helping people grow families. Pregmune exists to ensure that fewer patients are left without answers — and more are given a clear path forward.

Get Started For Physicians
Our Mission

Replacing "Unexplained" with Understanding

Pregmune was founded to address one of the most persistent gaps in fertility care: patients transferring healthy embryos, doing everything right, and still being told their infertility was unexplained.

The science of reproductive immunology has long existed — but it has often been too complex, fragmented, or inaccessible to integrate into routine fertility care. Pregmune's mission is to simplify that science, translate immune data into actionable clinical insight, and replace guesswork with clarity.

Today, Pregmune stands at the intersection of rigorous science and compassionate care — combining the clinical legacy of decades of reproductive immunology practice with a patient-centered, data-driven approach that can scale to reach physicians and patients everywhere.

The Pregmune team
Our Story

How Pregmune Came to Be

Pregmune grew out of more than a decade of reproductive immunology practice — and a conviction that this expertise should be available to every patient who needs it.

2004 — Clinical Foundation
Braverman Reproductive Immunology
In 2004, Dr. Jeffrey Braverman established Braverman Reproductive Immunology (BRI), a New York–based IVF center that integrated reproductive immunology into clinical care from the outset. He was subsequently joined by friend and colleague Dr. Andrea Vidali. From the beginning, BRI treated patients with recurrent pregnancy loss, recurrent implantation failure, and endometriosis — achieving live birth rates approaching 80% in patients with five or more prior losses through targeted immune testing and treatment.
Founded — Making RI Accessible
Pregmune Is Born
Pregmune was spun out of BRI in 2020 by Dr. Andrea Vidali with a single purpose: to extend the expertise developed over decades of clinical practice beyond a single center. Built on a foundation of decades of clinical experience diagnosing and treating the most challenging fertility patients, Pregmune was designed to harness an extensive data asset — millions of data points of clinical history, immune biomarker testing, immune treatment protocols, and outcomes from thousands of patients — and make that same level of immune evaluation accessible to fertility physicians and patients everywhere.
Scale Up
Expanding Access, Building Evidence
With its clinical and data foundation in place, Pregmune focused on scale: streamlining patient onboarding, expanding insurance verification and prior authorization support, and reducing friction at every step of the process. Physician relationships deepened across the reproductive medicine community, and Pregmune's data assets continued to grow — adding new biomarker profiles, treatment outcomes, and real-world evidence with each patient served. The result is a continuously improving evidence base that makes every subsequent assessment more informed than the last.
Today — Intersection of Science and Care
Data-Driven, Patient-Centered
Pregmune continues to grow at the intersection of rigorous science and compassionate care. Using proprietary machine-learning algorithms, Pregmune analyzes comprehensive immune, metabolic, hormonal, and genetic profiles to provide physicians and patients with the clearest possible picture of why a pregnancy hasn't happened — and what can be done about it.
Leadership & Scientific Advisory

Our Scientific Leadership

Pregmune's scientific and operational leadership combines deep reproductive immunology expertise with the clinical and data foundation needed to translate immune science into meaningful patient outcomes.

Nadera Mansouri-Attia
Nadera Mansouri-Attia, PhD
Chief Scientific Officer & COO
An internationally trained reproductive immunologist, Dr. Mansouri-Attia brings deep expertise in the immune factors underlying pregnancy loss and implantation failure. As CSO and COO, she leads Pregmune's scientific strategy and operations, overseeing the patient experience, physician relationships, and the translation of complex immune data into actionable clinical insights.
Prof. Antonio Gargiulo
Prof. Antonio Gargiulo
Scientific Advisor
A leading expert in minimally invasive gynecologic surgery and reproductive medicine, Professor Gargiulo brings deep expertise in complex fertility cases and endometriosis to Pregmune's scientific direction.
Dr. Melvin Thornton II
Dr. Melvin Thornton II
Scientific Advisor
A specialist in reproductive endocrinology and infertility, Dr. Thornton brings clinical perspective and research depth to Pregmune's work in identifying and addressing immune contributors to reproductive failure.
Dr. Andrea Vidali
Dr. Andrea Vidali
Founding Scientific Advisor
A partner at Braverman Reproductive Immunology and the founder of Pregmune, Dr. Vidali has pioneered the integration of reproductive immunology into fertility care, building the clinical foundation on which Pregmune's science rests.
Get Started

Ready to find the answers?

Whether you're a patient seeking clarity or a physician looking to expand your diagnostic toolkit, Pregmune is here to help.

Get Started For Physicians

Medical Disclaimer

Patients and physicians should always consult with a licensed medical professional before making any clinical decisions, including starting or discontinuing any treatment. Any information provided by Pregmune, including but not limited to the IRMA Report, AIMY Report, test results, risk estimates, supporting documentation, email communications or other related content (collectively, "Pregmune Content"), is intended for informational purposes only. This content is not medical advice and should not be used as a substitute for professional medical evaluation, diagnosis, or treatment. Pregmune Content is not a recommendation for any specific treatment plan, therapy, medication, or course of action. It is designed to support, not replace, the relationship between patients and their qualified healthcare providers. Pregmune does not provide medical care, and its reports and communications should never delay or override clinical judgment.